The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
AACR 2024 | How can we implement MRD testing in colorectal cancer?
Paolo Manca, MD, Memorial Sloan Kettering Cancer Center, New York, NY, provides an overview of minimal residual disease (MRD) testing for colorectal cancer. Despite multiple clinical trials assessing MRD in colorectal cancer, it has not been as effective in real world conditions, where hidden metastases that are only observable with other techniques can occur. Additional research is needed to validate MRD in the clinic. This interview took place at American Association for Cancer Research (AACR) Annual Meeting 2024 in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
